SCHEMBL5545910

SCHEMBL5545910

FC(F)(F)C(F)(F)Oc1cccc(CNc2cc[c]cc2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.42
MEN1 O00255 5/20 0.42
KMT2A Q03164 5/20 0.42
ALDH1A1 P00352 4/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
THRB P10828 2/20 0.42
PKM P14618 2/20 0.42
RAB9A P51151 2/20 0.42
BLM P54132 2/20 0.42
KDM4E B2RXH2 2/20 0.42
GAA P10253 2/20 0.42
TDP1 Q9NUW8 2/20 0.41
LMNA P02545 2/20 0.41
RECQL P46063 1/20 0.41
CASP6 P55212 1/20 0.41
P2RX7 Q99572 1/20 0.41
FFAR1 O14842 8/20 0.40
KDM5A P29375 1/20 0.39
KDM4C Q9H3R0 1/20 0.39
KDM5B Q9UGL1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5535976 0.89 KDM5A (0.48) MAPTMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL5541667 0.88 CNR1 (0.41) MEN1KMT2AL3MBTL1KDM4EP2RX7
SCHEMBL5546371 0.86 MTNR1A (0.40)
SCHEMBL5536443 0.83 HDAC1 (0.41) MAPTMEN1KMT2AL3MBTL1RAB9A
SCHEMBL5536027 0.79 HIF1A (0.59) MAPTMEN1KMT2AALDH1A1RAB9A
SCHEMBL5541187 0.77 KIF11 (0.39) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL5546744 0.77 CNR1 (0.51) KDM5AKDM4CKDM5BMAPK14
SCHEMBL5546068 0.76 FFAR1 (0.46) L3MBTL1KDM4EP2RX7FFAR1KCNN3
SCHEMBL5544937 0.76 FFAR1 (0.58) L3MBTL1KDM4EP2RX7FFAR1KCNN3
SCHEMBL5541454 0.75 ABCB1 (0.43) MAPTMEN1KMT2AALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAPT 4117/4885MEN1 3295/4885KMT2A 4267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.